Table 4 Simulated economic outcomes in the Diabetes Prevention Program intervention groups over a lifetime: Sensitivity analyses
Variable | Lifestyle Intervention vs. Placebo Intervention | Metformin Intervention vs. Placebo Intervention | ||||
|---|---|---|---|---|---|---|
∆ Cost, $ | ∆ QALYa | ∆ Cost/∆ QALY, $ | ∆ Cost, $ | ∆ QALYa | ∆ Cost/∆ QALY,$ | |
Base-case analysis | 635 | 0.57 | 1,124 | 3,922 | 0.13 | 31,286 |
Age 25–44 y | −395 | 0.63 | Cost-saving | 2,574 | 0.27 | 9,573 |
Age 45–54 y | 489 | 0.63 | 781 | 4,024 | 0.13 | 30,013 |
Age 55–64 y | 1,807 | 0.53 | 3,409 | 4,413 | 0.07 | 64,904 |
Age 65–74 y | 2,617 | 0.39 | 6,646 | 4,119 | 0.02 | 173,593 |
Age ≥ 75 y | 2,508 | 0.21 | 11,700 | 3,255 | 0.01 | 273,207 |
Reduced costb | -3,696 | 0.57 | Cost-saving | 220 | 0.13 | 1,755 |
20 % reduced effectiveness | 1,417 | 0.46 | 3,102 | 4,084 | 0.11 | 38,145 |
50 % reduced effectiveness | 2,371 | 0.30 | 7,886 | 4,307 | 0.80 | 52,562 |
Reduced costb and 20 % reduced effectiveness | -2,181 | 0.41 | Cost-saving | 635 | 0.10 | 6,576 |
Reduced costb and 50 % reduced effectiveness | -348 | 0.23 | Cost-saving | 1,198 | 0.06 | 20,994 |